Variant antibodies that bind ox40
AssigneeSorrento Therapeutics, Inc.
InventorMin Soo Kim
Life of this patent
Estimating the term…
Loading patent…
AssigneeSorrento Therapeutics, Inc.
InventorMin Soo Kim
Estimating the term…
The present disclosure provides variant anti-OX40 antibodies that mimic the activity of OX40L by behaving as an agonist against receptor OX40 to enhance T cell clonal expansion and differentiation. The variant anti-OX40 antibodies exhibit improved binding affinity for OX40 and improved agnostic activity, compared to a wild type anti-OX40 antibody (wild type 2B4 clone) from which the variant clones are derived. The variant anti-OX40 antibodies specifically bind OX40 receptors on activated T lymphocytes, stimulate proliferation of effector T cells, stimulate proliferation of effector T cells in the presence of regulatory T cells, and stimulate production of at least one cytokine from effector T cells.
A fully human antibody of an IgG class that binds OX40, comprising a heavy chain variable domain sequence that is at least 95% identical to the amino acid sequences of SEQ ID NO. 9, and a light chain variable domain sequence selected from the group consisting of SEQ ID NO. 3 (called 5-A6 herein), SEQ ID NO. 4 (called 5-A8 herein), SEQ ID NO. 5 (called 5-C8) herein), SEQ ID NO. 6 called 5-F5 herein SEQ ID NO. 7 (called 5-G8 herein), and SEQ ID NO. 8 (called 5-H6 herein).
A method for inducing proliferation of effector T cells, comprising:
A method for inducing effector T cells to increase production of at least one cytokine, comprising:
A method for inducing proliferation of effector T cells (Teff) in the presence of regulatory T cells (Treg), comprising:
Dependencies are inferred from the claim text.